• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome Original Articles
Conclusions: Generic clopidogrel was noninferior to Plavix with respect to the composite end point of death and recurrent hospitalization for ACS at 1 year among adults >65 years after an ACS hospitalization. Our findings support generic clopidogrel in ACS, which could lead to substantial healthcare cost savings.
Source: Circulation: Cardiovascular Quality and Outcomes - March 13, 2018 Category: Cardiology Authors: Ko, D. T., Krumholz, H. M., Tu, J. V., Austin, P. C., Stukel, T. A., Koh, M., Chong, A., de Melo, J. F., Jackevicius, C. A. Tags: Health Services, Mortality/Survival Original Articles Source Type: research

Abstract 211: Implications of the PEGASUS-TIMI 54 Trial for U.S. Clinical Practice Session Title: Poster Session II
Conclusions: In contemporary clinical practice, a minority of patients are on a P2Y12inhibitor beyond 1-year post-MI. Applying PEGASUS trial findings to clinical practice would result in a large increase in P2Y12 inhibitor use with a cost per ischemic event averted that is strongly influenced by the choice of therapy.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Bradley, S. M., Hess, G., Stewart, P., Armstrong, E., Farmer, S., Wasfy, J., Valle, J., Sandhu, A., Maddox, T. Tags: Session Title: Poster Session II Source Type: research

Abstract 138: Contemporary Patterns of Use of Antiplatelet Agents in Patients With Acute Myocardial Infarction: Insight From the National Cardiovascular Data Registry (NCDR) Session Title: Abstract Poster Session I and Reception
Conclusions: Our contemporary dataset shows a modest but significant increase in use of ticagrelor early and at discharge, with simultaneous decline in the use of clopidogrel and prasugrel in patients presenting with AMI.
Source: Circulation: Cardiovascular Quality and Outcomes - February 26, 2016 Category: Cardiology Authors: Basra, S. S., Wang, T. Y., Simon, D. N., Chiswell, K., Virani, S. S., Alam, M., Nambi, V., Denktas, A. E., Deswal, A., Ballantyne, C. M., Peterson, E. D., Jneid, H. M. Tags: Session Title: Abstract Poster Session I and Reception Source Type: research

Abstract 372: Health Outcomes Associated With Triple Antiplatelet Therapy for the Secondary Prevention of Atherothrombotic Events Session Title: Poster Session III
Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of atherothrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD), based on the findings of the TRA 2°P-TIMI 50 trial for patients without a history of stroke or transient ischemic attack. This analysis evaluated the health outcomes of triple antiplatelet therapy with vorapaxar when added to a standard care regimen of clopidogrel plus aspirin (ASA) in comparison with standard care alone, for patients without a history of transient ischemic attack or ...
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ozer-Stillman, I., Whalen, J. D., Bash, L. D., Oguz, M., Du, M., Singhal, P. K., Davies, G. M. Tags: Session Title: Poster Session III Source Type: research

{beta}-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction: Post Hoc Analysis From the CHARISMA Trial Original Articles
Conclusions— β-blocker use in patients with prior MI but no heart failure was associated with a lower composite cardiovascular outcome driven by lower risk of recurrent MI with no difference in mortality. However, β-blocker use was not associated with lower cardiovascular events in those without MI, with a suggestion of inferior outcome with regard to stroke risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00050817.
Source: Circulation: Cardiovascular Quality and Outcomes - November 18, 2014 Category: Cardiology Authors: Bangalore, S., Bhatt, D. L., Steg, P. G., Weber, M. A., Boden, W. E., Hamm, C. W., Montalescot, G., Hsu, A., Fox, K. A. A., Lincoff, A. M. Tags: Secondary prevention Original Articles Source Type: research

Abstract 132: The POWR Survey: Patient and Physician Perspectives on Outcomes Weighting in Revascularization. Session Title: Poster Session I
Conclusions: Patients and physicians agree on which outcomes are most (death and stroke)and least impactful (incision scar), but there is a lot of variability in between supporting the reporting of more adverse outcomes and not just those included in MACE.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Pandit, J. A., Gupta, V., Boyer, N., Ports, T. A., Yeghiazarians, Y., Boyle, A. J. Tags: Session Title: Poster Session I Source Type: research

Selecting Antiplatelet Therapy at the Time of Percutaneous Intervention for an Acute Coronary Syndrome: Weighing the Benefits and Risks of Prasugrel Versus Clopidogrel Original Articles
Conclusions— The expected benefits and risks of prasugrel versus clopidogrel depend highly on patient characteristics. The use of risk models could support individualized thienopyridine selection to maximize the benefits and safety of these drugs.
Source: Circulation: Cardiovascular Quality and Outcomes - January 15, 2013 Category: Cardiology Authors: Salisbury, A. C., Wang, K., Cohen, D. J., Li, Y., Jones, P. G., Spertus, J. A. Tags: Platelet function inhibitors, Other Treatment, Acute coronary syndromes, Acute myocardial infarction Original Articles Source Type: research